Edition:
United States

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

0.91USD
19 Jan 2017
Change (% chg)

$-0.01 (-1.62%)
Prev Close
$0.93
Open
$0.93
Day's High
$0.93
Day's Low
$0.89
Volume
7,204
Avg. Vol
33,493
52-wk High
$1.42
52-wk Low
$0.71

BLRX.OQ

Chart for BLRX.OQ

About

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in... (more)

Overall

No Ratios Available.

Financials

  BLRX.OQ Industry Sector
P/E (TTM): -- 44.51 30.50
EPS (TTM): -- -- --
ROI: -- -1.38 14.85
ROE: -- -1.00 16.27

BRIEF-Biolinerx announces initiation of Immuno-oncology Phase 2 study

* Biolinerx announces initiation of Immuno-oncology Phase 2 study to investigate combination of BL-8040 and keytruda for pancreatic cancer Source text for Eikon: Further company coverage:

Jan 17 2017

BRIEF-Biolinerx reports Q3 financial results

* Bioline RX Ltd - operating loss for three months ended September 30, 2016 amounted to $4.5 million versus operating loss of $3.6 million

Nov 22 2016

BRIEF-BioLine RX in-licenses novel anti-inflammatory treatment for dry eye syndrome under strategic collaboration with major global pharmaceutical company

* BioLine RX Ltd - in addition to des, biolinerx intends to explore potential use of bl-1230 in systemic inflammatory conditions

Nov 21 2016

BRIEF-Bioline RX discloses positive correlative data from phase 2A AML study

* Biolinerx discloses positive correlative data from phase 2a aml study and mechanism-of-action data for bl-8040 oncology platform at ash 2016

Nov 03 2016

BRIEF-Biolinerx announces initiation of Phase 2A trial of BL-8040 in combination with Keytruda

* Study will be conducted in us, israel and additional territories

Sep 20 2016

BRIEF-BioLineRx presents final results from Phase 2a trial for relapsed/refractory AML at SOHO conference

* BioLineRx presents final results from Phase 2a trial for relapsed/refractory AML at SOHO conference

Sep 08 2016

BRIEF-Bioline RX Ltd Q2 loss per share $0.07

* Qtrly loss per share $0.07 Source text for Eikon: Further company coverage:

Aug 11 2016

BRIEF-Bioline RX names Philip Serlin CEO

* Also appoints Mali Zeevi, as chief financial officer, effective october 10, 2016

Aug 11 2016

BRIEF-Biolinerx signs second clinical immuno-oncology collaboration agreement

* Biolinerx signs second clinical immuno-oncology collaboration agreement to investigate combination of bl-8040 and Keytruda for pancreatic cancer Source text for Eikon: Further company coverage:

Aug 08 2016

Earnings vs. Estimates